Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biotech growth moderates

Executive Summary

Global prescription sales of biotech drugs increased 12.5 percent in 2007 compared with 18.2 percent in 2006, according to IMS Health. Going forward, the research group predicts a more moderate growth environment through 2012 due to loss of exclusivity and competition from biosimilars, crowded therapy areas, payer reluctance to fund high-cost therapies and safety concerns. Sales gains in 2007 were led by oncologics and autoimmune agents, which each advanced by more than 24 percent. Overall biotech sales topped $75 million in 2007
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS049775

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel